Loading
Everything in development, the medicines held by this cancer's subtypes, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Multiple myeloma, drawn from the whole corpus: 209 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
1 medicines on record are linked to one of the types below rather than to Multiple myeloma itself. Grouped by the type that holds them; each list opens that type's own page.
High-risk cytogenetics.
Infections with T-cell redirecting therapy.
Cost and access.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
High-risk cytogenetics and extramedullary disease respond briefly to every class; no regimen closes the gap.
Infections are the main safety problem on bispecifics; hypogammaglobulinaemia and T-cell exhaustion need better mitigation than IVIG and dose de-intensification.
Delayed neurotoxicity (parkinsonism, cranial neuropathies) after BCMA CAR-T and second primary malignancies after cereblon modulators and CAR-T.
Also on OnCo: Side effects by symptom · Checkpoint side effects by organ · Side effect rates across a drug class · Survivorship planner.
Sequencing after BCMA failure: antigen loss (TNFRSF17 deletion) versus T-cell fitness; how to combine or alternate BCMA and GPRC5D agents.
Is transplant still needed? CARTITUDE-6 will answer; until then most fit patients receive high-dose melphalan.
Whether MRD-guided stopping is safe; whether MRD negativity at 10⁻⁶ equals cure for anyone.
Background: Minimal / molecular residual disease (MRD), MRD negativity (myeloma, 10⁻⁵ / 10⁻⁶), MRD-negative complete remission. Also on OnCo: Treatment journeys · Survivorship planner.
Precursor disease: treating high-risk smouldering myeloma prevents progression but may over-treat; population screening's mortality effect is unknown.
Also on OnCo: Symptoms and red flags · Early detection roadmap.
Cost and capacity: CAR-T slots, bispecific hospitalisation for step-up dosing, and lifelong therapy costs strain every health system.
Also on OnCo: Financial help · Coverage by country · Funding verdicts by country.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 90 changes by month →When this page itself was last checked or edited.
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma
FDA grants accelerated approval to iberdomide with daratumumab and hyaluronidase-fihj and dexamethasone for multiple myeloma The confirmatory requirement was still open 0.1 years later, when the FDA's table was read.
FDA approves isatuximab-irfc for subcutaneous injection for multiple myeloma indications
BLA accepted; PDUFA 27 December 2026